LianBio (LIANY)
ValueMarkers Composite Index
79% below intrinsic value ($1)
LianBio (LIANY) — VMCI valuation read
Across 120 indicators, LianBio (LIANY) lands at VMCI 60/100. The Healthcare sector median is 50, so the 10-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.
No material Form 4 disclosures landed on LIANY in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.
**Investor frame.** On Value, LIANY trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of -0.6x leaves covenant headroom for LIANY on the trailing balance sheet.
LIANY fell 1.4% over the trailing 7 days, with a -16.2% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.